Encorafenib (Braftovi)

From HemOnc.org - A Hematology Oncology Wiki
(Redirected from Encorafenib (LGX818))
Jump to: navigation, search

General information

Class/mechanism (from NCI Drug Dictionary): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway.

Diseases for which it is used

History of changes in FDA indication

Also known as

  • Code name: LGX818
  • Brand name: Braftovi